Literature DB >> 22407943

ERBB2 overexpression triggers transient high mechanoactivity of breast tumor cells.

Mireille Martin1, Karla Müller, Cristina Cadenas, Matthias Hermes, Mareike Zink, Jan G Hengstler, Josef A Käs.   

Abstract

Biomechanical properties of tumor cells play an important role for the metastatic capacity of cancer. Cellular changes of viscoelastic features are prerequisite for cancer progression since they are essential for proliferation and metastasis. However, only little is known about the way how expression of oncogenes influences these biomechanical properties. To address this aspect we used a breast cancer cell line with inducible expression of an oncogenic version of ERBB2. ERBB2 is known to be correlated with bad prognosis in breast cancer. Cell elasticity was determined by the Optical Stretcher, where suspended cells are deformed by two slightly divergent laser beams. We found that induction of ERBB2 caused remarkable biomechanical alterations of the MCF-7 cells after 24 h: the cells actively contracted in response to mechanical stimuli, a phenomenon known as mechanoactivation. After this period, as the cells became senescent, the mechanoactivity returned to control levels. Time-resolved gene array analysis revealed that mechanoactivation was accompanied by temporal upregulation of 46 cytoskeletal genes. A possible role of these genes in tumor progression was investigated by expression analyses of 766 breast cancer patients. This showed an association of 12 out of these 46 genes with increased risk of metastasis. Our results demonstrate that overexpression of ERBB2 causes mechanoactivation of tumor cells, which may enhance tumor cell motility fostering distant metastasis.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22407943     DOI: 10.1002/cm.21023

Source DB:  PubMed          Journal:  Cytoskeleton (Hoboken)        ISSN: 1949-3592


  5 in total

1.  Prognostic signatures of breast cancer: Perou's molecular subtypes and Schmidt's metagenes.

Authors:  Cristina Cadenas
Journal:  EXCLI J       Date:  2012-05-09       Impact factor: 4.068

2.  Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors.

Authors:  Marcus Schmidt; Patrick Micke; Mathias Gehrmann; Jan G Hengstler
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

3.  Highlight report: Validation of prognostic genes in lung cancer.

Authors:  Rosemarie Marchan
Journal:  EXCLI J       Date:  2014-05-06       Impact factor: 4.068

4.  Cancer research: from prognostic genes to therapeutic targets.

Authors:  Rosemarie Marchan
Journal:  EXCLI J       Date:  2014-12-09       Impact factor: 4.068

5.  S100A11 is required for efficient plasma membrane repair and survival of invasive cancer cells.

Authors:  Jyoti K Jaiswal; Stine P Lauritzen; Luana Scheffer; Masakiyo Sakaguchi; Jakob Bunkenborg; Sanford M Simon; Tuula Kallunki; Marja Jäättelä; Jesper Nylandsted
Journal:  Nat Commun       Date:  2014-05-08       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.